Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Generating Real-world Evidence from Unstructured Clinical Notes to Examine Clinical Utility of Genetic Tests: Use Case in BRCAness
Zhao, Yiqing , Weroha, Saravut J., Goode, Ellen L. , Wang, Chen , Wang, Chen , Liu, Hongfang

Mayo Clinic

No container title available | December 17, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-41553/v3 Get It

Abstract Background: Next-generation sequencing provides comprehensive information about individuals’ genetic makeup and is commonplace in oncology clinical practice. However, the utility of genetic information in clinical decision-making process has not been examined extensively from a real-world, data-driven perspective. Through mining real-world data (RWD) from clinical notes, we could extract patients’ genetic information and further associate treatment decisions with genetic information.Methods: We proposed a real-world evidence (RWE) study framework that incorporates context-based natural language processing (NLP) methods and data quality examination before final association analysis. The framework was demonstrated in a Foundation-tested women cancer cohort (N=196). Upon retrieval of patients’ genetic information using NLP system, we assessed the completeness of genetic data captured in unstructured clinical notes according to a genetic data-model. We examined the distribution of different topics regarding BRCA1/2 throughout patients’ treatment process, and then analyzed the association between BRCA1/2 mutation status and the discussion/prescription of targeted therapy. Results: We identified seven topics in clinical context of genetic mentions including: Information, Evaluation, Insurance, Order, Negative, Positive, and Variants of unknown significance (VUS). Our rule-based system achieved a precision of 0.87, recall of 0.93 and F-measure of 0.91. Our machine learning system achieved a precision of 0.901, recall of 0.899 and F-measure of 0.9 for four-topic classification and a precision of 0.833, recall of 0.823 and F-measure of 0.82 for seven-topic classification. We found in result-containing sentences, capture of BRCA1/2 mutation information was 75%, but detailed variant information (e.g. variant types) is largely missing. Using cleaned RWD, significant associations were found between BRCA1/2 positive mutation and targeted therapies.Conclusions: In conclusion, we demonstrated a framework to generate RWE using RWD from different clinical sources. Rule-based NLP system achieved the best performance for resolving contextual variability when extracting RWD from unstructured clinical notes. Data quality issues such as incompleteness and discrepancies exist thus manual data cleaning is needed before further analysis can be performed. Finally, we were able to use cleaned RWD to evaluate real-world utility of genetic information to initiate a prescription of targeted therapy.
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Perrot, Aurore , Plesner, Torben , Usmani, Saad Z. , Kumar, Shaji , Hulin, Cyrille , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Roussel, Murielle , Jaccard, Arnaud , Delforge, Michel , Karlin, Lionel, Arnulf, Bertrand , Chari, Ajai , He, Jianming , Ho, Kai Fai, Rampelbergh, Rian Van , Uhlar, Clarissa, Wang, Jianping , Kobos, Rachel, Gries, Katharine S. , Fastenau, John , Orlowski, Robert Z. , Jaccard, Arnaud , Chari, Ajai , Perrot, Aurore , Ramasamy, Karthik , Usmani, Saad , Nahi, Hareth , Roussel, Murielle , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Karlin, Lionel , Weisel, Katja C

Mayo Clinic

Journal of Clinical Oncology | December 16, 2020 | Volume: 39 | Issue: 3 | Pages: 227-237

10.1200/jco.20.01370 | PMID 33326255 Get It

PURPOSE To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 ( P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.
Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy
Wang, Juan , Ilyas, Sumera I. , Ilyas, Sumera

Mayo Clinic

Expert Opinion on Investigational Drugs | December 15, 2020 | Volume: 30 | Issue: 4 | Pages: 429-438

10.1080/13543784.2021.1865308 | PMID 33322977 Get It

Fluid Management During Kidney Transplantation: A Consensus Statement of the Committee on Transplant Anesthesia of the American Society of Anesthesiologists
Wagener, Gebhard , Kroepfl, Elizabeth, Diaz, Geraldine C., Giordano, Chris , James, West, Kindscher, James D., Moguilevitch, Marina , Nicolau‐Raducu, Ramona , Planinsic, Raymond M. , Rosenfeld, David M. , Lindberg, Scott , Pivalizza, Evan G. , Bezinover, Dmitri , Wang, Cynthia , Schumann, Roman

Mayo Clinic

Transplantation | December 15, 2020 | Volume: 105 | Issue: 8 | Pages: 1677-1684

10.1097/tp.0000000000003581 | PMID 33323765 Get It

Background. Intraoperative fluid management may affect the outcome after kidney transplantation. However, the amount and type of fluid administered, and monitoring techniques vary greatly between institutions and there are limited prospective randomized trials and meta-analyses to guide fluid management in kidney transplant recipients. Methods. Members of the American Society of Anesthesiologists (ASA) committee on transplantation reviewed the current literature on the amount and type of fluids (albumin, starches, 0.9% saline, and balanced crystalloid solutions) administered and the different monitors used to assess fluid status, resulting in this consensus statement with recommendations based on the best available evidence. Results. Review of the current literature suggests that starch solutions are associated with increased risk of renal injury in randomized trials and should be avoided in kidney donors and recipients. There is no evidence supporting the routine use of albumin solutions in kidney transplants. Balanced crystalloid solutions such as Lactated Ringer are associated with less acidosis and may lead to less hyperkalemia than 0.9% saline solutions. Central venous pressure is only weakly supported as a tool to assess fluid status. Conclusions. These recommendations may be useful to anesthesiologists making fluid management decisions during kidney transplantation and facilitate future research on this topic.
Epidemiology and Outcomes of Young-Onset Esophageal Adenocarcinoma: An Analysis from a Population-Based Database
Codipilly, Don C. , Sawas, Tarek , Dhaliwal, Lovekirat , Johnson, Michele L., Lansing, Ramona, Wang, Kenneth K. , Leggett, Cadman L. , Katzka, David A. , Iyer, Prasad G. , Leggett, Cadman L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 11, 2020 | Volume: 30 | Issue: 1 | Pages: 142-149

10.1158/1055-9965.epi-20-0944 | PMID 33328255 Get It

AbstractBackground:Esophageal adenocarcinoma is a lethal cancer with rising incidence. There are limited data in younger (&lt;50 years) patients with esophageal adenocarcinoma. We aimed to assess time trends in the incidence and outcomes of “young-onset” esophageal adenocarcinoma using a population-based database.Methods:We queried the Surveillance, Epidemiology, and End Results 9 database to identify patients with esophageal adenocarcinoma between 1975 and 2015. Patients were stratified into three age strata: &lt;50, 50 to 69, and ≥70 years. Staging was stratified as localized, regional, and distant. Trends in incidence, disease stage, and survival were assessed in three periods (1975–89, 1990–99, and 2000–2015). Univariate and multivariate models were created to identify predictors of mortality.Results:Esophageal adenocarcinoma incidence has increased in patients &lt;50 years of age, with an annual percentage change of 2.9% (95% confidence interval, 1.4%–4.4%) from 1975 to 2015. Young-onset esophageal adenocarcinoma presented at more advanced stages (regional + distant) compared with older patients (84.9% vs. 67.3%; P &lt; 0.01), with increasing proportion of advanced stages over the study period. These patients also experienced poorer 5-year esophageal adenocarcinoma–free survival compared with older patients (22.9%% vs. 29.6%; P &lt; 0.01), although this finding was attenuated on stage-stratified analysis.Conclusions:Young-onset esophageal adenocarcinoma, while uncommon, is rising in incidence. Concerningly, the proportion of advanced disease continues to increase. Young-onset esophageal adenocarcinoma also presents at more advanced stages, resulting in poorer esophageal adenocarcinoma–free survival.Impact:Patients with esophageal adenocarcinoma younger than 50 years present at more advanced stages with higher esophageal adenocarcinoma–specific mortality compared with older peers. Current diagnostic and management strategies for young-onset esophageal adenocarcinoma may need to be reevaluated.
Completeness of Social and Behavioral Determinants of Health in Electronic Health Records: A case study on the Patient-Provided Information from a minority cohort with sexually transmitted diseases
Kshatriya, Bhavani Singh Agnikula , Zhang, Rui , Wang, Yanshan , Wang, Yanshan , Balls‐Berry, Joyce E. , Freeman, William D.

Mayo Clinic

No container title available | December 10, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-123744/v1 Get It

Abstract IntroductionRacially and ethnically diverse minorities often experience the disease burden of sexually transmitted infections or diseases (STD) more often than their White counterparts. Yet, little is known about the connection of STD systematic discrimination, racism, and social and behavioral determinants. Plus, little to no details exists related to how this information is recorded in their Electronic Health Records (EHRs). The objective of this study is to assess the completeness of social and behavioral determinants of health (SDOH) data in the EHRs of a minority cohort with STD.Materials and Methods2,993 minority patients diagnosed with a STD at the Mayo Clinic were identified for this study. A natural language processing (NLP) algorithm was applied on the Patient-Provided Information (PPI) in their EHRs to extract SDOH information in six domains that are associated with STD, namely alcohol use, substance use, sexual activity, sexual orientation, housing status, and employment status. The completeness of SDOH was assessed in terms of documentation, breadth, and density.ResultsOur study indicates that nearly half of 2,993 patients did not have SDOH-related PPI records in their EHRs whereas the patients who had SDOH-related PPI records had well-documented records for five out of six SDOH domains, including alcohol use, substance use, sexual activity, housing status, and employment status, except for sexual orientation. A total of 1,504 patients had PPI in their EHRs for at least one of six SDOH domains, which is about 50.3% of the study cohort. Most SDOH domains have a short time span of 1 year, with up to 18 years of record data. Our analysis also indicated that education and age have a significant impact on the recording of SDOH-related PPI records. Patients that are female, older, and higher educated tend to have more SDOH information available in their records.Discussion and ConclusionWe assessed the completeness of SDOH information recorded in the PPI from patients’ EHRs. Due to large amounts of missing SDOH information in the PPI, future research is needed to integrate accurate and robust SDOH related data for downstream research and the impact of systematic discrimination on how this information is collected and interpreted in the EHRs.
Lipid metabolism dysfunction in progranulin mutation carriers: Unbiased metabolomics reveals strong relationship to clinical status in FTLD
Wang, Ping , Heuer, Hilary W. , Karydas, Anna M., Ljubenkov, Peter A. , Rosen, Howard J. , Boxer, Adam L. , Investigators, ARTFL and LEFFTDS Consortia, VandeVrede, Lawren , Rojas, Julio C. , Boeve, Bradley F. , Investigators, ARTFL and LEFFTDS Consortia

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.046594 Get It

AbstractBackgroundHeterozygous progranulin (GRN) mutations are an important cause of familial Frontotemporal Lobar Degeneration (f‐FTLD) associated with TDP‐43 pathology. The cellular role of progranulin remains unclear, but alterations in lipid metabolism and lysosomal function have been suggested. Better understanding the pathophysiology of progranulin deficiency is critical as several clinical trials are underway in this population, and fluid biomarkers are urgently needed to assess pharmacodynamic effects. Therefore, we conducted an unbiased metabolomic analysis in GRN mutation carriers and family member controls, and identified at least two classes of lipids altered in symptomatic GRN carriers.MethodsMatched plasma and CSF samples were obtained from GRN mutation carriers (46 plasma, 36 CSF) and age‐matched blood relatives (36 plasma, 18 CSF). Untargeted metabolite detection was conducted via LC‐MS/MS in both plasma (1389 compounds) and CSF (508 compounds) by Metabolon. To identify important compounds in differentiating these groups, we conducted an unbiased analysis between family controls, asymptomatic carriers, and symptomatic carriers using univariate one‐way ANOVA with post‐hoc Fisher’s LSD corrected for false discovery rate (FDR) and partial least squares ‐ discriminant analysis (PLS‐DA, Metaboanalyst). For compounds identified by this unbiased approach, correlation with measures of disease severity was analyzed via linear regression, controlling for age and gender.ResultsIn plasma, 22 compounds were identified as significant in discriminating between groups via ANOVA (FDR<0.05), and 17/22 were also identified by PLS‐DA (VIP>2.4). Of these, 21/22 compounds were lipids; 11 were sphingomyelins. Comparatively, in the relatively lipid‐poor CSF samples, 6/15 compounds identified by PLS‐DA (VIP>2.0) were phosphatidylcholines. Pathway impact analysis revealed a large impact from the GRN mutation on sphingolipids in plasma and glycerophospholipids in CSF. In secondary analyses, sphingomyelins were elevated in plasma from symptomatic carriers, while phosphatidylcholines were decreased in CSF. Secondary analyses showed these compounds were correlated with clinical measures of disease severity, including MoCA and CDR+NACC‐FTLD.ConclusionIncreased plasma concentration of sphingomyelin and decreased CSF phosphatidylcholines are both associated with worse clinical status in FTLD‐GRN. These findings suggest that impaired lipid metabolism could play a pathogenic role in FTLD‐GRN. Targeted lipidomic measures in plasma and CSF may potentially reveal useful clinical trial biomarkers.
Genome‐wide association study of tau‐PET: Association of variant near NTNG2 with resistance to tau deposition
Wang, Xuewei K, Przybelski, Scott A. , Pillai, Sheela Kumari Raghavan, Kosel, Matthew , Batzler, Anthony, Radford, Jonathan Graff, Lowe, Val J. , Petersen, Ronald C. , Ramanan, Vijay K. , Knopman, David S. , Mielke, Michelle M. , Jack, Clifford R. , Ross, Owen A. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.044321 Get It

AbstractBackgroundTau deposition is a key biological feature of Alzheimer’s disease (AD) that is closely related to cognitive impairment. However, it remains poorly understood why certain individuals may be more susceptible to tau accumulation while others are more resistant. The recent availability of tau positron emission tomography (tau‐PET) provides an opportunity to test the hypothesis that genetic factors are associated with differential tau deposition.MethodsWe performed a genome‐wide association study (GWAS) of tau‐PET on a sample of 754 individuals over age 50 (mean age 72.4 years, 54.6% men, 87.4% cognitively unimpaired) from the population‐based Mayo Clinic Study of Aging. Following genotyping with the Illumina GSA array and standard quality control, 515,206 single nucleotide polymorphisms (SNPs) were tested for association with entorhinal cortex 18F‐flortaucipir tau‐PET burden using linear regression under an additive genetic model and covarying for age and sex.ResultA genome‐wide significant association was identified for rs75546066, an intergenic SNP on chromosome 9 between MED27 (mediator complex subunit 27) and NTNG2 (netrin G2), with the minor (A) allele associated with lower tau burden (p=2.85 x 10‐8, β=‐0.48). Linkage disequilibrium and public expression quantitative trait loci (eQTL) data suggested a functional relationship between rs75546066 and NTNG2, the latter of which is highly expressed in the brain. In addition to this novel finding, three SNPs within MAPT (microtubule‐associated protein tau) displayed nominal associations to tau‐PET burden, including rs3785883 (p=0.04, β=0.07) which was previously associated with higher cerebrospinal fluid tau in an independent cohort. No associations with tau‐PET burden were identified for the APOE (apolipoprotein E) ɛ4 or ɛ2 alleles or for genotyped SNPs previously associated with AD in large case‐control studies.ConclusionTo our knowledge, this study represents the first reported neuroimaging GWAS of tau pathology. Our findings confirm the association of MAPT with tau burden and nominate the rs75546066‐NTNG2 locus as a novel potential protective influence against tau pathology which warrants further functional characterization. Our data also supports the inference that tau accumulation may have a genetic architecture distinct from APOE and other known AD susceptibility genes, which may have implications for improved risk stratification and therapeutic targeting models.
Investigating gene expression changes underlying selective hippocampal vulnerability in Alzheimer’s disease using a translational neuropathology approach
Crist, Angela M. , Hinkle, Kelly M., Wang, Xue , Lesser, Elizabeth R. , Azu, Nkem O. , Frankenhauser, Isabelle , Liesinger, Amanda M., Serie, Daniel, DeTure, Michael , Cook, Casey , Petrucelli, Leonard , Petersen, Ronald C. , Duara, Ranjan , Graff‐Radford, Neill R. , Allen, Mariet , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Asmann, Yan W. , Moloney, Christina M. , Labuzan, Sydney A. , Matchett, Billie J. , Duara, Ranjan , Carrasquillo, Minerva M. , Li, Hu, Ross, Owen A. , Dickson, Dennis W. , Carter, Rickey E. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S2 | Pages: No page available

10.1002/alz.041199 Get It

AbstractBackgroundUsing an objective mathematical algorithm to assess corticolimbic involvement of neurofibrillary tangle pathology, we identified three AD subtypes: hippocampal sparing (HpSp) AD, typical AD, and limbic predominant AD. Typical AD brains were representative of the expected patterns of hippocampal and cortical involvement as outlined by Braak tangle stage. In contrast, we discovered an extreme phenotype that exists outside of the Braakian‐concept of neurofibrillary tangle patterns. Hippocampal sparing AD cases demonstrate unexpected sparing of the hippocampus relative to severely involved association cortices and limbic predominant AD cases demonstrate inundation of the hippocampus relative to mildly involved association cortices. Using these AD subtypes, our objective was to leverage our understanding of disease spectrum to uncover transcriptomic changes that underlie selective vulnerability of the hippocampus in AD.MethodWe performed RNA‐sequencing in 40 neuropathologically diagnosed AD cases (10 HpSp, 20 Typical and 10 Limbic) and 15 controls to uncover gene expression changes associated with phenotype differences allowing us to prioritize 44 genes for further exploration. Validation with NanoString and quantification with digital pathology were performed in an expanded cohort of 158 AD cases (36 HpSp, 79 Typical and 35 Limbic) and 32 controls. We quantified digital pathology measures of early tangle pathology (CP13), mature tangle pathology (Ab39), amyloid‐β (33.1.1). In addition, we measured cellular markers for microglia (CD68), endothelia (CD34), and astroglia (GFAP). Deep learning based prediction models were employed, which nominated the SLC38A2 gene as a predictor of AD.ResultThe SLC38A2 gene was originally prioritized in our RNA‐sequencing data based upon differential expression between controls and typical AD. We observed upregulation of SLC38A2 in all AD subtypes. RNA‐seq gene expression measures validated well with NanoString for SLC38A2 (R=0.97, p<0.001). Regression analysis identified early tangle (p=0.011) and late tangle measures (p=0.026) as significant predictors of gene expression, but not amyloid measures (p=0.74). Microgliosis approached significance (p=0.052), but with no contribution from endothelial cell burden (p=0.17) or astrogliosis (p=0.58). Age approached significance (p=0.06), but not sex (p=0.88) or APOE‐ε4 status (p=0.10).ConclusionOur data supports consideration of intra‐disease divergence with regard to case stratification and may reveal genes previously masked by heterogeneity of cohorts.
A consensus proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation
Ping, Lingyan , Zhou, Maotian , Yin, Luming, Higginbotham, Lenora A., Guajardo, Andrew, White, Bartholomew, Troncoso, Juan C. , Thambisetty, Madhav , Montine, Thomas J. , Lee, Eddie B, Trojanowski, John Q. , Beach, Thomas G. , Reiman, Eric M. , Haroutunian, Vahram , Schadt, Eric E. , Zhang, Bin , Ertekin‐Taner, Nilüfer , Golde, Todd E. , Jager, Philip L. De , Hajjar, Ihab , Shulman, Joshua M. , Seyfried, Nicholas T. , Johnson, Erik C. B. , Dammer, Eric B. , Duong, Duc M , Seyfried, Nicholas T , Wang, Minghui , Dickson, Dennis W. , Petyuk, Vladislav , Bennett, David A. , Wingo, Thomas S , Rangaraju, Srikant , Lah, James J. , Levey, Allan I.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S2 | Pages: No page available

10.1002/alz.039504 Get It

AbstractBackgroundOur understanding of the biological changes in the brain associated with Alzheimer’s disease (AD) pathology and cognitive impairment remains incomplete. Unbiased discovery proteomic analysis of AD brain can help to increase our understanding of these changes.MethodWe analyzed dorsolateral prefrontal cortex, precuneus, and temporal cortex of control, asymptomatic AD, and AD brains from multiple different centers by label‐free quantitative mass spectrometry and weighted protein co‐expression analysis to obtain a consensus protein co‐expression network of AD brain. We also analyzed cerebrospinal fluid to investigate potential biomarkers related to this network.ResultThe network consisted of 13 protein co‐expression modules. Six of these modules correlated with amyloid‐β plaque burden, tau neurofibrillary tangle burden, cognitive function, and clinical functional status, and were altered in asymptomatic AD, AD, or in both disease states. These six modules reflected synaptic, mitochondrial, sugar metabolism, extracellular matrix, cytoskeletal, and RNA binding/splicing biological functions. The identified protein network modules were preserved in a community‐based cohort analyzed by a different quantitative mass spectrometry approach. They were also preserved in temporal lobe and precuneus brain regions. Some of the modules were influenced by aging, and showed changes in other neurodegenerative diseases such as frontotemporal dementia and corticobasal degeneration. The module most strongly associated with AD pathology and cognitive impairment was the sugar metabolism module. This module was enriched in AD genetic risk factors, and was also highly enriched in microglia and astrocyte protein markers associated with an anti‐inflammatory state, suggesting that the biological functions it represents may serve a protective role in AD. Proteins from the sugar metabolism module were increased in cerebrospinal fluid from asymptomatic AD and AD cases, highlighting their potential as biomarkers of the altered brain network.ConclusionIn this study of >2000 brains and nearly 400 cerebrospinal fluid samples by quantitative proteomics, we identify proteins and biological processes in AD brain that may serve as therapeutic targets and fluid biomarkers for the disease.